## Marcus Bantscheff

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6388159/publications.pdf

Version: 2024-02-01

114 papers 18,981 citations

23567 58 h-index 21540 114 g-index

128 all docs

128 docs citations

128 times ranked

27187 citing authors

#	Article	IF	CITATIONS
1	Mass-spectrometry-based draft of the human proteome. Nature, 2014, 509, 582-587.	27.8	1,697
2	Quantitative mass spectrometry in proteomics: a critical review. Analytical and Bioanalytical Chemistry, 2007, 389, 1017-1031.	3.7	1,448
3	Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature, 2011, 478, 529-533.	27.8	1,354
4	Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nature Biotechnology, 2007, 25, 1035-1044.	17.5	979
5	Catalytic in vivo protein knockdown by small-molecule PROTACs. Nature Chemical Biology, 2015, 11, 611-617.	8.0	879
6	A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response. Nature, 2012, 488, 404-408.	27.8	822
7	Tracking cancer drugs in living cells by thermal profiling of the proteome. Science, 2014, 346, 1255784.	12.6	812
8	Quantitative mass spectrometry in proteomics: critical review update from 2007 to the present. Analytical and Bioanalytical Chemistry, 2012, 404, 939-965.	3.7	695
9	Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nature Biotechnology, 2011, 29, 255-265.	17.5	597
10	Design of amidobenzimidazole STING receptor agonists with systemic activity. Nature, 2018, 564, 439-443.	27.8	505
11	Thermal proteome profiling for unbiased identification of direct and indirect drug targets using multiplexed quantitative mass spectrometry. Nature Protocols, 2015, 10, 1567-1593.	12.0	481
12	A Scalable Approach for Protein False Discovery Rate Estimation in Large Proteomic Data Sets. Molecular and Cellular Proteomics, 2015, 14, 2394-2404.	3.8	350
13	Mass-spectrometry-based draft of the Arabidopsis proteome. Nature, 2020, 579, 409-414.	27.8	328
14	Increased expression of BIN1 mediates Alzheimer genetic risk by modulating tau pathology. Molecular Psychiatry, 2013, 18, 1225-1234.	7.9	321
15	Systematic analysis of protein turnover in primary cells. Nature Communications, 2018, 9, 689.	12.8	280
16	Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation. Science, 2020, 368, 387-394.	12.6	274
17	Confident Phosphorylation Site Localization Using the Mascot Delta Score. Molecular and Cellular Proteomics, 2011, 10, S1-S12.	3.8	247
18	Thermal proteome profiling monitors ligand interactions with cellular membrane proteins. Nature Methods, 2015, 12, 1129-1131.	19.0	244

#	Article	IF	CITATIONS
19	Measuring and Managing Ratio Compression for Accurate iTRAQ/TMT Quantification. Journal of Proteome Research, 2013, 12, 3586-3598.	3.7	238
20	lon Coalescence of Neutron Encoded TMT 10-Plex Reporter Ions. Analytical Chemistry, 2014, 86, 3594-3601.	6.5	235
21	Robust and Sensitive iTRAQ Quantification on an LTQ Orbitrap Mass Spectrometer. Molecular and Cellular Proteomics, 2008, 7, 1702-1713.	3.8	219
22	Antimalarial efficacy of MMV390048, an inhibitor of <i>Plasmodium</i> phosphatidylinositol 4-kinase. Science Translational Medicine, 2017, 9, .	12.4	204
23	Thermal profiling reveals phenylalanine hydroxylase as an off-target of panobinostat. Nature Chemical Biology, 2016, 12, 908-910.	8.0	189
24	Multiplexed Proteome Dynamics Profiling Reveals Mechanisms Controlling Protein Homeostasis. Cell, 2018, 173, 260-274.e25.	28.9	186
25	High-Resolution Enabled TMT 8-plexing. Analytical Chemistry, 2012, 84, 7188-7194.	6.5	181
26	Proteome-wide solubility and thermal stability profiling reveals distinct regulatory roles for ATP. Nature Communications, 2019, 10, 1155.	12.8	181
27	Class III Phosphatidylinositol 4-Kinase Alpha and Beta Are Novel Host Factor Regulators of Hepatitis C Virus Replication. Journal of Virology, 2009, 83, 10058-10074.	3.4	179
28	Mass spectrometric proteome analyses of synovial fluids and plasmas from patients suffering from rheumatoid arthritis and comparison to reactive arthritis or osteoarthritis. Electrophoresis, 2002, 23, 3445-3456.	2.4	174
29	Potent and selective chemical probe of hypoxic signalling downstream of HIF- $\hat{l}\pm$ hydroxylation via VHL inhibition. Nature Communications, 2016, 7, 13312.	12.8	167
30	Biological plasticity rescues target activity in CRISPR knock outs. Nature Methods, 2019, 16, 1087-1093.	19.0	159
31	Mass Spectrometry-Based Proteomics in Preclinical Drug Discovery. Chemistry and Biology, 2012, 19, 72-84.	6.0	156
32	Human Proteinpedia enables sharing of human protein data. Nature Biotechnology, 2008, 26, 164-167.	17.5	155
33	Meltome atlasâ€"thermal proteome stability across the tree of life. Nature Methods, 2020, 17, 495-503.	19.0	152
34	New IDH1 mutant inhibitors for treatment of acute myeloid leukemia. Nature Chemical Biology, 2015, 11, 878-886.	8.0	151
35	SARS-CoV-2 drives JAK1/2-dependent local complement hyperactivation. Science Immunology, 2021, 6, .	11.9	144
36	A selective inhibitor reveals PI3Kγ dependence of TH17 cell differentiation. Nature Chemical Biology, 2012, 8, 576-582.	8.0	136

#	Article	IF	CITATIONS
37	Revealing promiscuous drug–target interactions by chemical proteomics. Drug Discovery Today, 2009, 14, 1021-1029.	6.4	134
38	Discovery and Characterization of GSK2801, a Selective Chemical Probe for the Bromodomains BAZ2A and BAZ2B. Journal of Medicinal Chemistry, 2016, 59, 1410-1424.	6.4	133
39	Chemoproteomics-Based Design of Potent LRRK2-Selective Lead Compounds That Attenuate Parkinson's Disease-Related Toxicity in Human Neurons. ACS Chemical Biology, 2011, 6, 1021-1028.	3.4	131
40	Extended pharmacodynamic responses observed upon PROTAC-mediated degradation of RIPK2. Communications Biology, 2020, 3, 140.	4.4	125
41	Drug-perturbation-based stratification of blood cancer. Journal of Clinical Investigation, 2017, 128, 427-445.	8.2	124
42	PROTAC-Mediated Degradation of Bruton's Tyrosine Kinase Is Inhibited by Covalent Binding. ACS Chemical Biology, 2019, 14, 342-347.	3.4	122
43	Identifying drug targets in tissues and whole blood with thermal-shift profiling. Nature Biotechnology, 2020, 38, 303-308.	17.5	111
44	The emerging role of mass spectrometry-based proteomics in drug discovery. Nature Reviews Drug Discovery, 2022, 21, 637-654.	46.4	110
45	Delayed Fragmentation and Optimized Isolation Width Settings for Improvement of Protein Identification and Accuracy of Isobaric Mass Tag Quantification on Orbitrap-Type Mass Spectrometers. Analytical Chemistry, 2011, 83, 8959-8967.	6.5	102
46	Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia. Nature Cancer, 2021, 2, 1002-1017.	13.2	99
47	Ion Mobility Tandem Mass Spectrometry Enhances Performance of Bottom-up Proteomics. Molecular and Cellular Proteomics, 2014, 13, 3709-3715.	3.8	98
48	The Commonly Used PI3-Kinase Probe LY294002 Is an Inhibitor of BET Bromodomains. ACS Chemical Biology, 2014, 9, 495-502.	3.4	97
49	Chemoproteomic approaches to drug target identification and drug profiling. Bioorganic and Medicinal Chemistry, 2012, 20, 1973-1978.	3.0	88
50	Targeted data acquisition for improved reproducibility and robustness of proteomic mass spectrometry assays. Journal of the American Society for Mass Spectrometry, 2010, 21, 1668-1679.	2.8	83
51	Chemical Proteomics Reveals Ferrochelatase as a Common Off-target of Kinase Inhibitors. ACS Chemical Biology, 2016, 11, 1245-1254.	3.4	82
52	Nonparametric Analysis of Thermal Proteome Profiles Reveals Novel Drug-binding Proteins*. Molecular and Cellular Proteomics, 2019, 18, 2506-2515.	3.8	75
53	Chemoproteomics-based kinome profiling and target deconvolution of clinical multi-kinase inhibitors in primary chronic lymphocytic leukemia cells. Leukemia, 2011, 25, 89-100.	7.2	74
54	Tau interactome mappingÂbased identification of Otub1 as Tau deubiquitinase involved in accumulation of pathological Tau forms in vitro and in vivo. Acta Neuropathologica, 2017, 133, 731-749.	7.7	74

#	Article	IF	CITATIONS
55	Affinity Profiling of the Cellular Kinome for the Nucleotide Cofactors ATP, ADP, and GTP. ACS Chemical Biology, 2013, 8, 599-607.	3.4	73
56	Selectively Targeting the Kinome-Conserved Lysine of PI3K $\hat{l}$ as a General Approach to Covalent Kinase Inhibition. Journal of the American Chemical Society, 2018, 140, 932-939.	13.7	73
57	Identification of KasA as the cellular target of an anti-tubercular scaffold. Nature Communications, 2016, 7, 12581.	12.8	72
58	A Modular Probe Strategy for Drug Localization, Target Identification and Target Occupancy Measurement on Single Cell Level. ACS Chemical Biology, 2016, 11, 2541-2550.	3.4	70
59	The structure based design of dual HDAC/BET inhibitors as novel epigenetic probes. MedChemComm, 2014, 5, 342-351.	3.4	66
60	Discovery and Characterisation of Highly Cooperative FAKâ€Degrading PROTACs. Angewandte Chemie - International Edition, 2021, 60, 23327-23334.	13.8	58
61	THPP target assignment reveals EchA6 as an essential fatty acid shuttle in mycobacteria. Nature Microbiology, 2016, 1, 15006.	13.3	57
62	Femtomol sensitivity post-digest 180 labeling for relative quantification of differential protein complex composition. Rapid Communications in Mass Spectrometry, 2004, 18, 869-876.	1.5	55
63	Chemical Proteomic Analysis Reveals the Drugability of the Kinome of <i>Trypanosoma brucei</i> . ACS Chemical Biology, 2012, 7, 1858-1865.	3.4	53
64	Chemoproteomics Reveals Time-Dependent Binding of Histone Deacetylase Inhibitors to Endogenous Repressor Complexes. ACS Chemical Biology, 2014, 9, 1736-1746.	3.4	52
65	Cell surface thermal proteome profiling tracks perturbations and drug targets on the plasma membrane. Nature Methods, 2021, 18, 84-91.	19.0	49
66	Discovery of GSK8612, a Highly Selective and Potent TBK1 Inhibitor. ACS Medicinal Chemistry Letters, 2019, 10, 780-785.	2.8	48
67	Chemical and Pathway Proteomics. Molecular and Cellular Proteomics, 2008, 7, 1887-1901.	3.8	43
68	Hsp90 inhibition differentially destabilises MAP kinase and TGF-beta signalling components in cancer cells revealed by kinase-targeted chemoproteomics. BMC Cancer, 2012, 12, 38.	2.6	41
69	Monitoring Cell-surface N-Glycoproteome Dynamics by Quantitative Proteomics Reveals Mechanistic Insights into Macrophage Differentiation. Molecular and Cellular Proteomics, 2017, 16, 770-785.	3.8	41
70	Chemical proteomics reveals target selectivity of clinical Jak inhibitors in human primary cells. Scientific Reports, 2019, 9, 14159.	3.3	39
71	Identification of Linker Regions and Domain Borders of the Transcription Activator Protein NtrC fromEscherichia coliby Limited Proteolysis,In-GelDigestion, and Mass Spectrometryâ€. Biochemistry, 1999, 38, 11012-11020.	2.5	36
72	Interrogating the Druggability of the 2-Oxoglutarate-Dependent Dioxygenase Target Class by Chemical Proteomics. ACS Chemical Biology, 2016, 11, 2002-2010.	3.4	36

#	Article	IF	Citations
73	H-Score, a Mass Accuracy Driven Rescoring Approach for Improved Peptide Identification in Modification Rich Samples. Journal of Proteome Research, 2010, 9, 5511-5516.	3.7	34
74	A computational method for detection of ligand-binding proteins from dose range thermal proteome profiles. Nature Communications, 2020, 11, 5783.	12.8	34
75	Ca <sup>2+</sup> signals critical for egress and gametogenesis in malaria parasites depend on a multipass membrane protein that interacts with PKG. Science Advances, 2021, 7, .	10.3	34
76	Differential proteome analysis and mass spectrometric characterization of germ line development-related proteins of Caenorhabditis elegans. Proteomics, 2004, 4, 2283-2295.	2.2	32
77	Improved Proteomics-Based Drug Mechanism-of-Action Studies Using 16-Plex Isobaric Mass Tags. Journal of Proteome Research, 2021, 20, 1792-1801.	3.7	29
78	Quantitative mass spectrometry in proteomics. Analytical and Bioanalytical Chemistry, 2012, 404, 937-938.	3.7	27
79	Activation of the Amino Acid Response Pathway Blunts the Effects of Cardiac Stress. Journal of the American Heart Association, 2017, 6, .	3.7	26
80	Differential Kinobeads Profiling for Target Identification of Irreversible Kinase Inhibitors. ACS Chemical Biology, 2017, 12, 2515-2521.	3.4	26
81	Dimerization of signalling modules of the EvgAS and BvgAS phosphorelay systems. BBA - Proteins and Proteomics, 2000, 1478, 341-354.	2.1	25
82	Proteome Analysis of Diseased Joints from Mice Suffering from Collagen-Induced Arthritis. Clinical Chemistry and Laboratory Medicine, 2003, 41, 1622-32.	2.3	24
83	Discovery of a Highly Selective Tankyrase Inhibitor Displaying Growth Inhibition Effects against a Diverse Range of Tumor Derived Cell Lines. Journal of Medicinal Chemistry, 2017, 60, 5455-5471.	6.4	24
84	BRD4 methylation by the methyltransferase SETD6 regulates selective transcription to control mRNA translation. Science Advances, 2021, 7, .	10.3	23
85	Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia. Nature Cancer, 2021, 2, 1002-1017.	13.2	23
86	Mass spectrometry approaches to monitor protein–drug interactions. Methods, 2012, 57, 430-440.	3.8	22
87	Pathway Proteomics and Chemical Proteomics Team Up in Drug Discovery. Neurodegenerative Diseases, 2007, 4, 270-280.	1.4	19
88	Kruidenier et al. reply. Nature, 2014, 514, E2-E2.	27.8	18
89	Advanced proteomics approaches to unravel protein homeostasis. Drug Discovery Today: Technologies, 2019, 31, 99-108.	4.0	17
90	Discovery of Novel Small Molecules that Activate Satellite Cell Proliferation and Enhance Repair of Damaged Muscle. ACS Chemical Biology, 2016, 11, 518-529.	3.4	16

#	Article	IF	Citations
91	Optimization of Orally Bioavailable PI3Kl̂ Inhibitors and Identification of Vps34 as a Key Selectivity Target. Journal of Medicinal Chemistry, 2020, 63, 638-655.	6.4	15
92	An improved two-step calibration method for matrix-assisted laser desorption/ionization time-of-flight mass spectra for proteomics. Rapid Communications in Mass Spectrometry, 2002, 16, 1892-1895.	1.5	14
93	Loss of N-Glycanase 1 Alters Transcriptional and Translational Regulation in K562 Cell Lines. G3: Genes, Genomes, Genetics, 2020, 10, 1585-1597.	1.8	14
94	CDK12 inhibition reduces abnormalities in cells from patients with myotonic dystrophy and in a mouse model. Science Translational Medicine, 2020, $12$ , .	12.4	12
95	Probing the tertiary structure of multidomain proteins by limited proteolysis and mass spectrometry. European Journal of Mass Spectrometry, 1998, 4, 279.	0.7	11
96	Rational design and molecular characterization of a chimaeric response regulator protein. Journal of Molecular Biology, 2001, 310, 283-290.	4.2	10
97	Mutational Analysis of Glycogen Synthase Kinase $3\hat{l}^2$ Protein Kinase Together with Kinome-Wide Binding and Stability Studies Suggests Context-Dependent Recognition of Kinases by the Chaperone Heat Shock Protein 90. Molecular and Cellular Biology, 2016, 36, 1007-1018.	2.3	9
98	Patient-derived gene and protein expression signatures of NGLY1 deficiency. Journal of Biochemistry, 2022, 171, 187-199.	1.7	9
99	Structure-function relationships in the Bvg and Evg two-component phosphorelay systems. International Journal of Medical Microbiology, 2000, 290, 317-323.	3.6	8
100	Evaluation of Data Analysis Strategies for Improved Mass Spectrometry-Based Phosphoproteomics. Analytical Chemistry, 2010, 82, 9843-9849.	6.5	8
101	Mass Spectrometry-Based Chemoproteomic Approaches. Methods in Molecular Biology, 2012, 803, 3-13.	0.9	8
102	Wilhelm et al. reply. Nature, 2017, 547, E23-E23.	27.8	7
103	A Bayesian semi-parametric model for thermal proteome profiling. Communications Biology, 2021, 4, 810.	4.4	6
104	Inhibition of BET Recruitment to Chromatin As An Effective Treatment for MLL-Fusion Leukaemia. Blood, 2011, 118, 55-55.	1.4	5
105	Discovery and Characterisation of Highly Cooperative FAKâ€Degrading PROTACs. Angewandte Chemie, 2021, 133, 23515-23522.	2.0	4
106	Mapping Protein Complexes Using Covalently Linked Antibodies and Isobaric Mass Tags. Methods in Molecular Biology, 2014, 1156, 279-291.	0.9	4
107	Affinity Enrichment for Target Deconvolution and. Methods in Molecular Biology, 2021, 2228, 237-252.	0.9	3
108	The multi-target aspect of an MmpL3 inhibitor: The BM212 series of compounds bind EthR2, a transcriptional regulator of ethionamide activation. Cell Surface, 2021, 7, 100068.	3.0	3

#	Article	IF	CITATIONS
109	Determination of Kinase Inhibitor Potencies in Cell Extracts by Competition Binding Assays and Isobaric Mass Tags. Methods in Molecular Biology, 2012, 803, 141-155.	0.9	2
110	Interval-Based Secretomics Unravels Acute-Phase Response in Hepatocyte Model Systems. Molecular and Cellular Proteomics, 2022, 21, 100241.	3.8	2
111	Quantifying Small Molecule-Induced Changes in Cellular Protein Expression and Posttranslational Modifications Using Isobaric Mass Tags. Methods in Molecular Biology, 2014, 1156, 431-443.	0.9	1
112	New Allosteric Inhibitors of Mutant IDH1 in Acute Myeloid Leukemia. Blood, 2015, 126, 787-787.	1.4	1
113	Affinity Purification of Proteins Binding to Kinase Inhibitors Immobilized on Self-Assembling Monolayers. Methods in Molecular Biology, 2012, 795, 149-160.	0.9	0
114	Monitoring Dynamic Changes of the Cell Surface Glycoproteome by Quantitative Proteomics. Methods in Molecular Biology, 2017, 1647, 47-59.	0.9	0